SH3765 not checked

Nanjing Sanhome

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Drug1: SH3765 will be administered orally twice daily on an intermittent dosing schedule with treatment on Days 1 to 4 each week of a 28-day treatment cycle. The dosage is 40 mg or 60mg twice daily (BID) (4 days on and 3 days off). Drug2:Fulvestrant injection is to be administered after taking the SH3765 tablets. It is given intramuscularly at a dose of 500 mg on Day 1 and Day 15 of Cycle 1, and…”In the company’s words, NCT07557004 on ClinicalTrials.gov
Tested for
HR+ / HER2- Advanced Breast Cancer
Main trialPhase 1
“Evaluate the efficacy and safety of the SH3765 tablet combined with fulvestrant in the treatment of patients with advanced HR-positive breast cancer”In the company’s words, NCT07557004 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 30 Jun 2027 A Study of SH3765 Tablets in Combination With Fulvestrant in Patients With HR+/HER2- Advanced Breast Cancer.
Phase 1Unknown Mar 2023 A Study to Investigate Safety and Tolerability of SH3765 Tablet in Patients With Advanced Malignant Tumor
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SH3765

Following is part of Solo: you see every change to SH3765 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in